These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 25962435

  • 41. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ, Li W, Kong LH, Wang GJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
    [Abstract] [Full Text] [Related]

  • 42. Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.
    Auewarakul CU, Huang S, Yimyam M, Boonmoh S.
    Acta Haematol; 2006 Feb; 116(2):114-9. PubMed ID: 16914906
    [Abstract] [Full Text] [Related]

  • 43. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.
    Clin Cancer Res; 2005 May 01; 11(9):3425-32. PubMed ID: 15867244
    [Abstract] [Full Text] [Related]

  • 44. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
    Pavlovsky C, Giere I, Moiraghi B, Pavlovsky MA, Aranguren PN, García J, Fernandez I, Bengió R, Milone J, Labanca V, Uriarte R, Lombardi V, Reinoso FG, Magariños AE, Martinez L, Murro H, Lastiri F, Pavlovsky S.
    Clin Lymphoma Myeloma Leuk; 2011 Jun 01; 11(3):280-5. PubMed ID: 21658656
    [Abstract] [Full Text] [Related]

  • 45. Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A case report and literature review.
    Li Y, Zhang Y, Meng X, Chen S, Wang T, Zhang L, Ma X.
    Medicine (Baltimore); 2024 Jan 19; 103(3):e36728. PubMed ID: 38241589
    [Abstract] [Full Text] [Related]

  • 46. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2014 Jan 19; 53(1-2):47-55. PubMed ID: 24629639
    [Abstract] [Full Text] [Related]

  • 47. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA.
    Mol Diagn Ther; 2016 Aug 19; 20(4):315-33. PubMed ID: 27220498
    [Abstract] [Full Text] [Related]

  • 48. Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia.
    Azad NA, Shah ZA, Pandith AA, Rasool R, Jeelani S.
    Biosci Rep; 2018 Oct 31; 38(5):. PubMed ID: 30054431
    [Abstract] [Full Text] [Related]

  • 49. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts.
    Burmeister T, Reinhardt R.
    Leuk Res; 2008 Apr 31; 32(4):579-85. PubMed ID: 17928051
    [Abstract] [Full Text] [Related]

  • 50. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
    Kelani R, Monem F.
    Int J Lab Hematol; 2015 Oct 31; 37(5):723-8. PubMed ID: 26059167
    [Abstract] [Full Text] [Related]

  • 51. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
    Qin YZ, Liu YR, Zhu HH, Li JL, Ruan GR, Zhang Y, Jiang Q, Jiang H, Li LD, Chang Y, Huang XJ, Chen SS.
    Int J Lab Hematol; 2008 Aug 31; 30(4):317-23. PubMed ID: 18665830
    [Abstract] [Full Text] [Related]

  • 52. The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study.
    Savasoglu K, Payzin KB, Ozdemirkiran F, Subasioglu A, Yilmaz AF.
    Leuk Lymphoma; 2017 Aug 31; 58(8):1958-1962. PubMed ID: 27924671
    [Abstract] [Full Text] [Related]

  • 53. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report.
    Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, DI Raimondo F, Manzella L.
    Anticancer Res; 2019 Jul 31; 39(7):3949-3954. PubMed ID: 31262926
    [Abstract] [Full Text] [Related]

  • 54. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chroniques.
    Lancet Oncol; 2010 Nov 31; 11(11):1029-35. PubMed ID: 20965785
    [Abstract] [Full Text] [Related]

  • 55. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
    Bourlon C, Hernandez-Mata C, Vargas-Serafín C, Bourlon MT, Tuna-Aguilar E, Aguayo A.
    Clin Lymphoma Myeloma Leuk; 2016 Aug 31; 16(8):453-9. PubMed ID: 27259590
    [Abstract] [Full Text] [Related]

  • 56. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK, Gruber FX, Wee L, Hovland R, Hjorth-Hansen H, Gedde Dahl T, Meyer P.
    Acta Haematol; 2009 Aug 31; 122(1):11-6. PubMed ID: 19641300
    [Abstract] [Full Text] [Related]

  • 57. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
    Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J, Andreasson C, Bua M, Olavarria E, Rahemtulla A, Dazzi F, Kanfer E, Goldman JM, Apperley JF.
    Leukemia; 2005 Apr 31; 19(4):507-12. PubMed ID: 15703781
    [Abstract] [Full Text] [Related]

  • 58. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A, Eskazan AE.
    Cancer; 2018 Oct 01; 124(19):3806-3818. PubMed ID: 29694669
    [Abstract] [Full Text] [Related]

  • 59. [Monitoring of bcr/abl fusion gene by interphase-dual-color and dual-fusion fluorescence in situ hybridization in CML after allo-HSCT].
    Qian SX, Li JY, Zhang R, Hong M, Qiu HR, Li L, Xu W, Sheng RL, Wu HX.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun 01; 14(3):577-81. PubMed ID: 16800946
    [Abstract] [Full Text] [Related]

  • 60. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb 01; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.